← Russell 3000 cross-section

PRME Prime Medicine, Inc.

Trailing twelve months to 2025-12-31 · as filed 2026-03-03, not restated
Healthcare

Scale

Market cap
$646m
Revenue TTM
$5m
Net income TTM
$-201m
Free cash flow
$-167m
Composite score
37.7
Sector rank
#2276

Valuation

P / E
EV / EBITDA
EV / sales
101.0
FCF yield
-25.88%
Earnings yield vs 10-yr
-35.87pp

Earnings yield vs 10-yr compares what the business earns per pound invested against the 4.73% a 10-year US Treasury note pays for no equity risk. Negative means you are paying up front for growth not yet delivered.

Quality and growth

Net margin
-4,342.4%
EBITDA margin
-4,340.0%
ROE
-166.4%
ROIC
Revenue growth
55.3%

Insider activity, last 90 days

Net open-market
$0.00m
Buyers
0
Sellers
0

Open-market purchases and sales only. Grants, option exercises, gifts and shares withheld for tax are excluded: they are how people are paid, not what they think.

What management said

To date, we have financed our operations primarily through proceeds from sales of preferred stock and from our public offerings, including our initial public offering, or IPO, and through payments from our collaboration partners.Prime Medicine, Inc., 10-K, period ended 2025-12-31, filed 2026-03-03

Read the full passage →